Inhibition of microRNA miR-92a induces apoptosis and necrosis in human acute promyelocytic leukemia

Authors
Mohammadreza Sharifi
Rasoul Salehi
Yousof Gheisari
Mohammad Kazemi
Department of Genetics and Molecular Biology, Pediatric Inherited Diseases Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: MicroRNAs (miRNAs) are endogenous non-coding RNAs, 19-25 nucleotides in length, involved in post-transcriptional regulation of gene expression in a considerable majority of mRNAs. Different aspects of cellular activities like cell growth, proliferation, and differentiation are regulated by miRNAs through their regulatory effects on particular RNA species. In many tumors, up- or down-regulation of different miRNAs has been reported. In acute myeloid leukemia, up-regulation of miR-92a has been reported in human in-vitro studies.
Materials and Methods: We performed inhibition of miR-92a in an acute promyelocytic leukemia cell line (HL-60), using locked nucleic acid (LNA) Antagomir. At different time points after LNA-anti-miR92a transfection, qRT-Real-Time-polymerase chain reaction (PCR) and Annexin-V/Propidium Iodide staining were performed and the data was analyzed using the Kruskal-Wallis and Mann-Whitney tests.
Results: The assessment of the apoptosis and necrosis indicates that miR-92a inhibition can decrease the viable HL-60 cells and this is at least partially due to induction of apoptosis.
Conclusion: These findings suggest the inhibition of miR-92a as a novel approach for treatment of Acute Promyelocytic Leukemia (APL).

Keywords

1. Griffiths-Jones SM. The micro RNA sequence database. Methods Mol Biol 2006;342:129-38.  Back to cited text no. 1
    
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.  Back to cited text no. 2
[PUBMED]    
3. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009;136:215-33.  Back to cited text no. 3
[PUBMED]    
4. McManus DD, Ambros V. Circulating MicroRNAs in cardiovascular disease. Circulation 2011;124:1908-10.  Back to cited text no. 4
[PUBMED]    
5. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nature cell Biol 2009;11:228-34.  Back to cited text no. 5
[PUBMED]    
6. Faller M, Guo F. MicroRNA biogenesis: There's more than one way to skin a cat. Biochim Biophys Acta 2008;1779:663-7.  Back to cited text no. 6
[PUBMED]    
7. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development 2005;132:4653-62.  Back to cited text no. 7
    
8. Dong C, Ji M, Ji C. microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther 2009;8:200-5.  Back to cited text no. 8
    
9. Trang P, Weidhaas J, Slack F. MicroRNAs as potential cancer therapeutics. Oncogene 2008;27:S52-S7.  Back to cited text no. 9
    
10. Cho WC. MicroRNAs in cancer: From research to therapy. Biochim Biophy Acta 2010;1805:209-17.  Back to cited text no. 10
    
11. O'Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annual review of immunology. 2012;30:295-312.  Back to cited text no. 11
    
12. Ruan K, Fang X, Ouyang G. MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer Lett 2009;285:116-26.  Back to cited text no. 12
[PUBMED]    
13. George G, Mittal RD. MicroRNAs: Potential biomarkers in cancer. Indian J Clin Biochem 2010;25:4-14.  Back to cited text no. 13
    
14. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 2009;119:2119.  Back to cited text no. 14
[PUBMED]    
15. Reddy SD, Gajula RP, Pakala SB, Kumar R. MicroRNAs and cancer therapy. Cancer Biol Ther 2010;9:479-82.  Back to cited text no. 15
[PUBMED]    
16. Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK. MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 2011;13:229.  Back to cited text no. 16
[PUBMED]    
17. Ørom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006;372:137-41.  Back to cited text no. 17
    
18. Zhao X, Yang L, Hu J, Ruan J. miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010;34:1078-82.  Back to cited text no. 18
[PUBMED]    
19. Yuan Y, Zeng ZY, Liu XH, Gong DJ, Tao J, Cheng HZ, et al. MicroRNA-203 inhibits cell proliferation by repressing ÄNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer 2011;11:57.  Back to cited text no. 19
[PUBMED]    
20. Xu J, Liao X, Wong C. Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer 2010;126:1029-35.  Back to cited text no. 20
[PUBMED]    
21. Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37:649-58.  Back to cited text no. 21
[PUBMED]    
22. Richard A. McPherson MR, Pincus Henry's Clinical Diagnosis and Management by Laboratory Methods. 21 st ed. Philadelphia: Sunders; 2007.  Back to cited text no. 22
    
23. Nagarajan L. Acute Myelogenous Leukemia: Genetics, Biology and Therapy. Germany: Springer Verlag; 2009.  Back to cited text no. 23
    
24. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:89-99.  Back to cited text no. 24
[PUBMED]    
25. Yoshizawa S, Ohyashiki J, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J 2012;2:e53.  Back to cited text no. 25
    
26. Nilsson S, Möller C, Jirström K, Lee A, Busch S, Lamb R, et al. Downregulation of miR-92a Is associated with aggressive breast cancer features and increased tumour Macrophage Infiltration. PLoS One 2012;7:e36051.  Back to cited text no. 26
    
27. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009;4:e5532.  Back to cited text no. 27
    
28. Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, Piaggio G, et al. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J 2009;23:3957-66.  Back to cited text no. 28
[PUBMED]    
29. Van Haaften G, Agami R. Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev 2010;24:1-4.  Back to cited text no. 29
[PUBMED]    
30. Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, et al. The miR-17 ~ 92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci 2009;106:2812.  Back to cited text no. 30
[PUBMED]    
31. Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Intl 2010;60:351-7.  Back to cited text no. 31
    
32. Hu G, Drescher KM, Chen XM. Exosomal miRNAs: Biological properties and therapeutic potential. Front Genet 2012;3:56.  Back to cited text no. 32
[PUBMED]    
33. Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S, et al. Estrogen receptor β1 expression is regulated by miR-92 in breast cancer. Cancer Res 2010;70:4778.  Back to cited text no. 33
[PUBMED]    
Advanced Biomedical Research
Volume 2014, January
January 2014
Pages 1-6